Literature DB >> 10551626

Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors.

T Sugahara1, Y Korogi, Y Shigematsu, L Liang, K Yoshizumi, M Kitajima, M Takahashi.   

Abstract

The degree of tumor malignancy generally correlates to tumor grade, and the direct measurement of tumor vasculature is desired. Dynamic susceptibility contrast magnetic resonance imaging can provide relative cerebral blood volume and, therefore, is one of the most reliable methods to evaluate tumor vasculature in vivo. Tumor vessel size is extremely variable due to complex tumor angiogenesis, and the gradient-echo echo-planar imaging (GE-EPI) technique, which is sensitive to the total vascular bed, is well suited for this purpose. As many studies have shown, dynamic susceptibility contrast magnetic resonance imaging is more useful for grading glioma than conventional magnetic resonance imaging. We found that this technique can also provide supplementary information to differentiate between malignant lymphoma and glioma because the absence of tumor neovascularization of malignant lymphoma leads to low rCBV, which is in contrast to those of malignant gliomas. Indeed, this technique can be used for the differentiation of extra-axial tumors such as between meningioma and neurinoma. Recently, this technique has been focused toward determining the stereotactic biopsy site, monitoring the embolization of effect in meningioma, or evaluation of treatment effects after radiation therapy. However, the value of tumor rCBV is affected by many conditions such as the T1 relaxivity effects of gadolinium in the extravascular space. To establish the usefulness of this technique, further examination will be needed.

Entities:  

Mesh:

Year:  1999        PMID: 10551626     DOI: 10.1097/00002142-199904000-00004

Source DB:  PubMed          Journal:  Top Magn Reson Imaging        ISSN: 0899-3459


  22 in total

Review 1.  Clinical applications of imaging biomarkers. Part 3. The neuro-oncologist's perspective.

Authors:  A Shenoy
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

2.  Definition of K(trans) and FA thresholds for better assessment of experimental glioma using high-field MRI: a feasibility study.

Authors:  T Engelhorn; M A Schwarz; A Hess; L Budinsky; P Pitann; I Eyüpoglu; A Doerfler
Journal:  Clin Neuroradiol       Date:  2013-12-18       Impact factor: 3.649

Review 3.  Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.

Authors:  G Thompson; S J Mills; D J Coope; J P B O'Connor; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 4.  Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy.

Authors:  Ramon Francisco Barajas; Soonmee Cha
Journal:  CNS Oncol       Date:  2014-11

5.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.

Authors:  Meng Law; Robert J Young; James S Babb; Nicole Peccerelli; Sophie Chheang; Michael L Gruber; Douglas C Miller; John G Golfinos; David Zagzag; Glyn Johnson
Journal:  Radiology       Date:  2008-03-18       Impact factor: 11.105

6.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

7.  Effect of contrast leakage on the detection of abnormal brain tumor vasculature in high-grade glioma.

Authors:  Peter S LaViolette; Mitchell K Daun; Eric S Paulson; Kathleen M Schmainda
Journal:  J Neurooncol       Date:  2013-11-29       Impact factor: 4.130

8.  MRI perfusion in determining pseudoprogression in patients with glioblastoma.

Authors:  Robert J Young; Ajay Gupta; Akash D Shah; Jerome J Graber; Timothy A Chan; Zhigang Zhang; Weiji Shi; Kathryn Beal; Antonio M Omuro
Journal:  Clin Imaging       Date:  2012-06-08       Impact factor: 1.605

9.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.

Authors:  Meng Law; Stanley Yang; James S Babb; Edmond A Knopp; John G Golfinos; David Zagzag; Glyn Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

10.  Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging.

Authors:  H R Arvinda; C Kesavadas; P S Sarma; B Thomas; V V Radhakrishnan; A K Gupta; T R Kapilamoorthy; S Nair
Journal:  J Neurooncol       Date:  2009-02-20       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.